ArticleCommunications biology2020
Anti-HIV agent azidothymidine decreases Tet(X)-mediated bacterial resistance to tigecycline in Escherichia coli.
Article in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 62 citations in OpenAlex.
- Article
- Evolution, Mechanisms, and Therapeutic Implications of Mobile Tetracycline Destructases.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Mechanistic insights into plasmid transfer inhibition in Enterobacterales by nucleoside analogues.npj antimicrobials and resistance · 2026Article
- Broxyquinoline enhances antibacterial activity of colistin and attenuates LPS-induced inflammation.Antimicrobial agents and chemotherapy · 2026Article
- New Frontiers for Old Medications: Repurposing Approved Drugs Against Gram-Negative Bacterial Infections.Microorganisms · 2025Review
- Binding assays enable discovery of Tet(X) inhibitors that combat tetracycline destructase resistance.Chemical science · 2025Article
- C10-Benzoate Esters of Anhydrotetracycline Inhibit Tetracycline Destructases and Recover Tetracycline Antibacterial Activity.ACS infectious diseases · 2025Article
- Methionine-driven methylation modification overcomes plasmid-mediated high-level tigecycline resistance.Nature communications · 2025Article
- Enzymatic synthesis of azide by a promiscuous N-nitrosylase.Nature chemistry · 2024Article
- Guanethidine Enhances the Antibacterial Activity of Rifampicin Against Multidrug-Resistant Bacteria.Microorganisms · 2024Article
- Guanethidine Restores Tetracycline Sensitivity in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Zidovudine in synergistic combination with nitrofurantoin or omadacycline:Antimicrobial agents and chemotherapy · 2024Article
- MALDI-TOF MS combined with AUC method for tigecycline susceptibility testing inJAC-antimicrobial resistance · 2024Article
- A promising metabolite, 9-aminominocycline, restores the sensitivity of tigecycline againstFrontiers in microbiology · 2024Article
- A Broad-Spectrum Horizontal Transfer Inhibitor Prevents Transmission of Plasmids Carrying Multiple Antibiotic Resistance Genes.Transboundary and emerging diseases · 2024Article
- Celastrol Combats Methicillin-Resistant Staphylococcus aureus by Targeting ΔAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram.Communications biology · 2023Article
- Oral and anal microbiome from HIV-exposed individuals: role of host-associated factors in taxa composition and metabolic pathways.NPJ biofilms and microbiomes · 2023Article
- Daunorubicin resensitizes Gram-negative superbugs to the last-line antibiotics and prevents the transmission of antibiotic resistance.iScience · 2023Article
- Natural flavonoids disrupt bacterial iron homeostasis to potentiate colistin efficacy.Science advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent emergence of high-level tigecycline resistance mediated by Tet(X3/X4) in Enterobacteriaceae undoubtably constitutes a serious threat for public health worldwide. Antibiotic adjuvant strategy makes antibiotic more effective against these resistant pathogens through interfering intrinsic resistance mechanisms or enhancing antibiotic actions. Herein, we screened a collection of drugs to identify compounds that are able to restore tigecycline activity against resistant pathogens. Encouragingly, we discovered that anti-HIV agent azidothymidine dramatically potentiates tigecycline activity against clinically resistant bacteria. Meanwhile, addition of azidothymidine prevents the evolution of tigecycline resistance in E. coli and the naturally occurring horizontal transfer of tet(X4). Evidence demonstrated that azidothymidine specifically inhibits DNA synthesis and suppresses resistance enzyme activity. Moreover, in in vivo infection models by Tet(X4)-expression E. coli, the combination of azidothymidine and tigecycline achieved remarkable treatment benefits including increased survival and decreased bacterial burden. These findings provide an effective regimen to treat infections caused by tigecycline-resistant Escherichia coli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.